Grant: CIHR Fellowship
Direct Payment
$150,000.00
Characterization of human cytotolytic T lymphocyte polyfunctionality and clonality in vaccinated melanoma patients at the single-cell level.
EF 2011-12
Résumé
Cancer therapy has made tremendous improvements in recent years through the optimization of surgical and non-surgical therapeutic approaches. Novel therapies, such as immunotherapy, are currently being evaluated in clinical trails to specifically target late-stage cancer.
Therapeutic vaccination or immunotherapy consists in the activation of the patient's own specialized cytolytic immune T cells, thereby leading to the specific killing of tumor cells. Contrary to vaccination against viruses, which promotes an immunological attack against a foreign pathogen, in cancer, the immune system must be instructed to recognize the subtle differences between normal and malignant cells. Consequently, an immune response against tumor cells is weaker than against virally-infected cells. To counter this, our team has designed novel vaccination procedures to improve the potency of the immune reaction generated against the tumor. Another aspect currently studied by our group consists in the molecular and functional characterization of the most powerful cytotoxic immune cells among the effectors CD8+ T cells.
Thus, using state-of-the art equipment, the goal of my project is to characterize tumor-specific cytolytic T lymphocytes at the single cell level. With this level of precision, we will be able to follow ex vivo the persistence of the anti-tumor immune response following vaccination of melanoma patients by monitoring the expression of unique T cell receptor sequences at defined time points and in various anatomical compartments. Furthermore, we will be able to further understand why certain CD8+ T cell subsets are more cytotoxic than others, and to pinpoint the mechanisms of T cell recruitment in well-defined clinical situations.
In conclusion, we are convinced that a better understanding of the biology of human immune system and of the intricate interactions between immune and cancer cells will led to significant improvements in the potency of immune-based therapies.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Switzerland
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
242321
Name
Gannon Philippe
Country
Switzerland
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Characterization of human cytotolytic T lymphocyte polyfunctionality and clonality in vaccinated melanoma patients at the single-cell level.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antigen-Specific T Cells; Cd8+ T Lymphocytes; Flow Cytometry; Immunotherapy; Melanoma; Polyfunctionality; Single-Cell Sorting; T Lymphocyte Differentiation; Tcr Clonotype Repertoire; Tumor-Antigen Specific Tetramers
Abstract
Cancer therapy has made tremendous improvements in recent years through the optimization of surgical and non-surgical therapeutic approaches. Novel therapies, such as immunotherapy, are currently being evaluated in clinical trails to specifically target late-stage cancer.
Therapeutic vaccination or immunotherapy consists in the activation of the patient's own specialized cytolytic immune T cells, thereby leading to the specific killing of tumor cells. Contrary to vaccination against viruses, which promotes an immunological attack against a foreign pathogen, in cancer, the immune system must be instructed to recognize the subtle differences between normal and malignant cells. Consequently, an immune response against tumor cells is weaker than against virally-infected cells. To counter this, our team has designed novel vaccination procedures to improve the potency of the immune reaction generated against the tumor. Another aspect currently studied by our group consists in the molecular and functional characterization of the most powerful cytotoxic immune cells among the effectors CD8+ T cells.
Thus, using state-of-the art equipment, the goal of my project is to characterize tumor-specific cytolytic T lymphocytes at the single cell level. With this level of precision, we will be able to follow ex vivo the persistence of the anti-tumor immune response following vaccination of melanoma patients by monitoring the expression of unique T cell receptor sequences at defined time points and in various anatomical compartments. Furthermore, we will be able to further understand why certain CD8+ T cell subsets are more cytotoxic than others, and to pinpoint the mechanisms of T cell recruitment in well-defined clinical situations.
In conclusion, we are convinced that a better understanding of the biology of human immune system and of the intricate interactions between immune and cancer cells will led to significant improvements in the potency of immune-based therapies.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gannon, Philippe
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~